The World Market for Biosimilars (EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies, Other), 4th Edition

Sep 22, 2013
195 Pages - Pub ID: KLI5123810
Abstract Table of Contents Search Inside Report Related Reports

The World Market for Biosimlars (EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies, Other), 4th Edition

This study, The World Market for Biosimilars, 4th Edition (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others), is designed to provide a comprehensive look at the various strategies being used by select worldwide generic companies in exploring the emerging area of biosimilars, the issues and trends that are shaping the marketplace, and the potential feasibility of providing biosimilars within the United States regulatory environment.

Generic drugs continue to represent one of the greatest values in healthcare and are of great importance in the area of biopharmaceuticals as well because these products are among the most expensive treatments currently on the market. Generic drug manufacturers are poised for strong growth in the future because the patent protection for a host of major biopharmaceuticals will expire and new legislative reforms in the generic drug approval process may facilitate bringing products to market. While there are many issues to address, the outlook for biosimilar promotion is favorable in the next five years. As part of its coverage, the report provides the following:
  • Scientific Differences of Pharmaceuticals and Biopharmaceuticals
  • Market Share of Biosimilar Sales in Comparison to Brand Sales
  • Marketed Biologics with Expired Patents
  • Marketed Biologics with Active Patents
  • Cost Savings From Biosimilar Use
  • World Biosimilar Market Potential by Region 2010-2017
  • World Biosimilar Market Potential by Biological Class 2010-2017 ( EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies, Other)
  • Biosimilars Pipeline by Company and Product Type
For the purposes of this study, Kalorama has focused on the market for products which have lost patent in key markets. Projections were made based on the progress that is occurring within the generic arena in terms of capabilities, capital, interest, and development of biopharmaceuticals. Kalorama has identified the biopharmaceuticals that have lost patent protection and are the first products produced by generic companies. As part of its coverage, the following companies were profiled:
  • 3SBio, Inc
  • Actavis, Inc.
  • Apotex, Inc.
  • Beijing Four Rings Biopharmaceutical Co Ltd
  • Biocad
  • Biocon Ltd .
  • Bio Sidus S.A.
  • BioXpress Therapeutics S.A.
  • Boehringer Ingelheim Gmbh
  • Celltrion, Inc.
  • Dong-A Pharmaceutical
  • Dr. Reddy’s Laboratories Limited
  • Epirus Biopharmaceuticals
  • Gedeon Richter
  • Harvest Moon Pharmaceuticals USA,
  • Hospira, Inc.
  • Kyowa Hakko Kirin Co., Ltd.
  • Merck & Company
  • Momenta Pharmaceuticals Inc
  • Phage Pharmaceuticals, Inc.
  • Ranbaxy Laboratories Limited
  • Reliance GeneMedix PLC
  • Reliance Life Sciences
  • Samsung Bioepis Co Ltd
  • Sandoz International GmbH
  • STADA Arzneimittel AG
  • TEVA Pharmaceutical Industries, Ltd.
  • Wockhardt Ltd.
  • Xiamen Amoytop Biotech Co Ltd.

Related Reports:

mhealth Markets Worldwide
Jul 8, 2015 - KLI5619950 - $3,995.00

The World Market for Point of Care (POC) Diagnostics
Jun 2, 2015 - KLI5573392 - $4,200.00

The World Market for Catheters (Urological, Intravenous, Cardiovascular Intervention, Angiography, Dialysis, PTCA, PICC, Oximetry and Surgical Catheters)
May 11, 2015 - KLI5555314 - $2,500.00

The Global Market for Medical Devices, 6th Edition
May 8, 2015 - KLI5554457 - $1,500.00

EMR 2015: The Market for Electronic Medical Records
May 1, 2015 - KLI5525862 - $4,200.00

Insulin Infusion Pumps: World Market Analysis
Mar 26, 2015 - KLI5510873 - $1,995.00

Implantable Infusion Pumps: World Market Analysis
Feb 26, 2015 - KLI5476346 - $1,500.00

Global Orthopedic Device Market (Hip, Knee, Spine, Extremities and Trauma Devices)
Feb 10, 2015 - KLI5467092 - $3,500.00

Ultrasound: World Market Analysis
Dec 17, 2014 - KLI5416203 - $1,500.00

The World Market for Veterinary Diagnostics
Dec 5, 2014 - KLI5399100 - $2,500.00

800.298.5603
Int'l: +1.240.747.3096
Questions?
Contact a research specialist >

Most Popular Research
Mass Spectrometry in Clinical Applications (MALDI-TOF, Triple Quad, QTRAP, Ion Trap, GCMS, Orbitrap & Ion-Orbitrap, QTOF, Other Mass Spec)
Next Generation Sequencing (NGS) Markets 2015 (Systems, Consumables, Services, Acquisitions, Agreements, Competitive Analysis, Platforms, Applications, Brand Ownership and Other Trends)
Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 6th Edition
Proteomics Markets for Clinical IVD Applications and Research Applications (Mass Spectrometry, Chromatography, Microarrays, Electrophoresis, Immunoassays, Other Technologies)
The Global Market for Biomarkers (Cancer Markers, Cardiac Markers, Blood Markers, Endocrine Markers, Infectious Disease and Neurological Disease Markers)
Library Preparation and Target Enrichment for Next Generation Sequencing Product Markets
Privacy Policy    |    Terms and Conditions    |    Site Map    |    Return Policy    |    Press    |    Help FAQs
Home About Us My Account Personal Library Contact Us
Copyright © 2015 Kalorama Information. All Rights Reserved.
A division of Market Research Group, LLC
8/30/2015 - 42
Contact Us: 800.298.5603 (U.S.)
or +1.240.747.3096 (Int'l)
Hours: Monday - Thursday: 5:30am - 6:30pm EST
Fridays: 5:30am - 5:30pm EST